Recommendations are now being made to the Glaucoma researchers in the field of ophthalmology.
Rather than focusing on how to improve the current treatments for Glaucoma patients, many are pushing for answers on how to alter the course of the disease.
In other words, by treating the cause of the disease, could doctors slow or completely stop the progression of vision loss?
Recent developments around this topic have led to the development of ROCK inhibitors (adenosine agonists), but some experts feel that the reason for choosing this treatment over those used previously has not been made clear.
What can the ROCK inhibitor do to change the way the disease affects the eye?
Is there a dysfunction of cellular mechanics that makes it more worthwhile?
The current treatments (prostalangin analogues) are affordable and relatively effective. They are not likely to be superseded by a medication that promises nothing new.
The goal, many feel, should be to disrupt the disease at its core, which will only be done through the use of disease-modifying therapies.
Currently, none exist.
Though there are those that are skeptical regarding the new treatment methods, they are being considered by the marketplace, and that could be a good sign that the private industry is seeking new answers for this horrible disease.
For more information, continue reading the full article here.
Leave Your Response